NCT03033511 2021-07-29
MERU
AbbVie
Phase 3 Terminated
Clinical Trials
4 trialsNCT02709889 2020-10-19
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
AbbVie
Phase 1/2 Terminated
NCT03026166 2020-07-17
A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
AbbVie
Phase 1/2 Terminated
NCT02819999 2020-03-12
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
AbbVie
Phase 1 Terminated